When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Gary Falk, MD, MS, Professor of Medicine, Director, Center for Esophageal and Swallowing Disorders, Cleveland Clinic, discusses Barrett’s esophagus and its treatment in patients with dysplasia. Summary: 1.…
NEW YORK (Reuters Health) – In a study of childhood cancer survivors, treatment with total body or abdominal irradiation was associated with an increased risk of diabetes later…
NEW YORK (Reuters Health) – Having a first-degree relative with breast cancer may slightly increase a person’s risk of colorectal cancer, Canadian researchers report in the International Journal…
NEW YORK (Reuters Health) – Therapy with denosumab appears to augment bone mineral density and lower the risk of fracture among men with prostate cancer undergoing androgen-deprivation therapy,…
NEW YORK (Reuters Health) – Don’t assume that lower limb salvage yields better functional and quality-of-life outcomes than amputation for children and adolescents with bone and soft tissue…
NEW YORK (Reuters Health) – Ovarian- and uterine-conserving surgery appears to be safe in premenopausal women with stage IA or IC epithelial ovarian cancer, with no adverse impact…
NEW YORK (Reuters Health) – As first-line therapy for advanced chronic lymphocytic leukemia, bendamustine produced significantly higher response rates and longer progression-free survival than chlorambucil in a phase…
NEW YORK (Reuters Health) – Both progression-free and overall survival are extended in patients with advanced non-small cell lung cancer treated with erlotinib following standard chemotherapy, according to…
NEW YORK (Reuters Health) – Due to hemoglobin degradation, delayed return of fecal occult blood tests (FOBTs) may miss colorectal adenomas and possibly also overt malignancy, according to…
NEW YORK (Reuters Health) – INR testing intervals of 4 weeks or less are typically recommended for patients on long-term warfarin therapy, but new research suggests that less…
